Propanc Biopharma has engaged a European Contract and Development Manufacturing Organization (CDMO) to produce its lead drug candidate, PRP, under GMP standards for an upcoming Phase 1b clinical trial involving 30-40 advanced cancer patients with solid tumors. This trial marks the first-in-human study of PRP, a novel proenzyme therapy administered intravenously once weekly, aiming to improve survival by inducing cancer cell differentiation rather than killing cells directly. PRP has already received Orphan Drug Designation for pancreatic cancer from the US FDA. The company plans to file the clinical trial application later this year, with hopes that positive results could significantly advance treatment options for late-stage cancer patients.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
